Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 10/20 | 0.60 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.60 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.60 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.60 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.60 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.60 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.60 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.60 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.60 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.60 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.60 |
| ▸ | DHODH | Q02127 | 5/20 | 0.56 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.48 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.45 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL630977 | 0.89 | PARP1 (0.56) | PARP1DHODHCHEK2 | |
| SCHEMBL10688649 | 0.77 | DHODH (0.67) | PARP1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL2982645 | 0.76 | FAAH (0.47) | PARP1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL30811244 | 0.74 | PARP1 (0.83) | PARP1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL29179972 | 0.74 | PARP1 (0.83) | PARP1HDAC3HDAC4HDAC1HDAC7 | |
| Phosphoric Acid SCHEMBL10686577 | 0.74 | DHODH (0.62) | PARP1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL6950091 | 0.72 | DHODH (0.69) | PARP1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL10686586 | 0.72 | DHODH (0.52) | PARP1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL505556 | 0.72 | DHODH (1.00) | PARP1HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL10212043 | 0.71 | DHODH (0.98) | PARP1HDAC3HDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1778637-B1 | FKBP-binding composition and pharmaceutical use thereof | AVENTIS PHARMA INC (US) | 2012-02-22 | — | — | EP | claimed |
| US-20080139556-A1 | FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF | AVENTIS PHARMACEUTICALS INC. (US) | 2008-06-12 | — | — | US | claimed |
| EP-1778637-A2 | FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF | Aventis Pharmaceuticals, Inc. (US) | 2007-05-02 | — | — | EP | claimed |
| WO-2006012256-A2 | FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF | AVENTIS PHARMACEUTICALS INC. (US) | 2006-02-02 | — | — | WO | claimed |
| US-7777042-B2 | N-sulfonylpipecolic acid derivative FKBP binding composition and pharmaceutical use thereof | AVENTIS PHARMACEUTICALS INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-20080139556-A1 | FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF | AVENTIS PHARMACEUTICALS INC. (US) | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139556-A1 | FKBP BINDING COMPOSITION AND PHARMACEUTICAL USE THEREOF | FKBP1A, FKBP1B, FKBP3 | PARP1 3364/4885HDAC3 1266/4885HDAC4 1994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.